Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Amortizatization of Intangibles (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Amortizatization of Intangibles data on record, last reported at $633000.0 in Q4 2025.

  • For Q4 2025, Amortizatization of Intangibles fell 74.75% year-over-year to $633000.0; the TTM value through Dec 2025 reached $3.7 million, down 63.36%, while the annual FY2025 figure was $3.7 million, 63.36% down from the prior year.
  • Amortizatization of Intangibles reached $633000.0 in Q4 2025 per TRDA's latest filing, down from $739000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $3.2 million in Q3 2024 and bottomed at -$145000.0 in Q2 2022.
  • Average Amortizatization of Intangibles over 4 years is $1.2 million, with a median of $1.1 million recorded in 2025.
  • Peak YoY movement for Amortizatization of Intangibles: surged 5687.5% in 2023, then plummeted 77.0% in 2025.
  • A 4-year view of Amortizatization of Intangibles shows it stood at $104000.0 in 2022, then soared by 1822.12% to $2.0 million in 2023, then increased by 25.41% to $2.5 million in 2024, then tumbled by 74.75% to $633000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Amortizatization of Intangibles were $633000.0 in Q4 2025, $739000.0 in Q3 2025, and $961000.0 in Q2 2025.